Optimization of a Urea-containing Series of Nicotinamide Phosphoribosyltransferase (NAMPT) Activators.

[1]  E. Sergienko,et al.  Boosting NAD+ with a small molecule that activates NAMPT , 2019, Nature Communications.

[2]  N. Klimova,et al.  Multi-targeted Effect of Nicotinamide Mononucleotide on Brain Bioenergetic Metabolism , 2019, Neurochemical Research.

[3]  E. White,et al.  Quantitative Analysis of NAD Synthesis-Breakdown Fluxes. , 2018, Cell metabolism.

[4]  D. Sinclair,et al.  Therapeutic Potential of NAD-Boosting Molecules: The In Vivo Evidence. , 2018, Cell metabolism.

[5]  J. Baur,et al.  NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR. , 2017, Cell metabolism.

[6]  Pete A. Williams,et al.  Nicotinamide and WLDS Act Together to Prevent Neurodegeneration in Glaucoma , 2017, Front. Neurosci..

[7]  M. Hirschey,et al.  Role of NAD+ and mitochondrial sirtuins in cardiac and renal diseases , 2017, Nature Reviews Nephrology.

[8]  N. Skelton,et al.  Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors. , 2016, Journal of medicinal chemistry.

[9]  W. Kiess,et al.  Physiological and pathophysiological roles of NAMPT and NAD metabolism , 2015, Nature Reviews Endocrinology.

[10]  Deepak Sampath,et al.  Inhibition of nicotinamide phosphoribosyltransferase (NAMPT) as a therapeutic strategy in cancer. , 2015, Pharmacology & therapeutics.

[11]  Karl H. Clodfelter,et al.  Identification of nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with no evidence of CYP3A4 time-dependent inhibition and improved aqueous solubility. , 2015, Bioorganic & medicinal chemistry letters.

[12]  L. Guarente,et al.  NAD+ and sirtuins in aging and disease. , 2014, Trends in cell biology.

[13]  Xukun Chen,et al.  Structural and Biochemical Analyses of the Catalysis and Potency Impact of Inhibitor Phosphoribosylation by Human Nicotinamide Phosphoribosyltransferase , 2014, Chembiochem : a European journal of chemical biology.

[14]  Karl H. Clodfelter,et al.  Structure-based identification of ureas as novel nicotinamide phosphoribosyltransferase (Nampt) inhibitors. , 2013, Journal of medicinal chemistry.

[15]  V. Schramm,et al.  Recycling nicotinamide. The transition-state structure of human nicotinamide phosphoribosyltransferase. , 2013, Journal of the American Chemical Society.

[16]  W. Kraus,et al.  New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs , 2012, Nature Reviews Molecular Cell Biology.

[17]  R. Petrelli,et al.  NMN/NaMN adenylyltransferase (NMNAT) and NAD kinase (NADK) inhibitors: chemistry and potential therapeutic applications. , 2011, Current medicinal chemistry.

[18]  Karine Gilbert,et al.  The Small Molecule GMX1778 Is a Potent Inhibitor of NAD+ Biosynthesis: Strategy for Enhanced Therapy in Nicotinic Acid Phosphoribosyltransferase 1-Deficient Tumors , 2009, Molecular and Cellular Biology.

[19]  V. Schramm,et al.  A phosphoenzyme mimic, overlapping catalytic sites and reaction coordinate motion for human NAMPT , 2009, Proceedings of the National Academy of Sciences.

[20]  V. Schramm,et al.  Weak coupling of ATP hydrolysis to the chemical equilibrium of human nicotinamide phosphoribosyltransferase. , 2008, Biochemistry.

[21]  S. Eom,et al.  Crystal structure of visfatin/pre-B cell colony-enhancing factor 1/nicotinamide phosphoribosyltransferase, free and in complex with the anti-cancer agent FK-866. , 2006, Journal of molecular biology.

[22]  C. Wolberger,et al.  Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme , 2006, Nature Structural &Molecular Biology.

[23]  J. Khan,et al.  Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents , 2006, Nature Structural &Molecular Biology.

[24]  S. Imai,et al.  The NAD Biosynthesis Pathway Mediated by Nicotinamide Phosphoribosyltransferase Regulates Sir2 Activity in Mammalian Cells* , 2004, Journal of Biological Chemistry.